This suggests that the effects of CDK4/6 inhibitors predominantly relate to T cell-extrinsic mechanisms, including increased antigen-presentation capacity of tumor cells or APCs that boost anti-tumor immunity (24, 25, 27). This evidence concerns the gene CDK4 and neoplasm.